Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Avoid Ten Lifestyle Group (TENG) by Steve Moore in ShareProphets
- Avoid Biome Technologies (BIOM) by Steve Moore in ShareProphets
- Buy Aviva (AV.) by Harvey Jones in The Motley Fool
- Buy CMC Markets (CMCX) by Harvey Jones in The Motley Fool
- Buy ITV (ITV) by Simon Watkins in The Motley Fool
- Buy Legal & General Group (LGEN) by Simon Watkins in The Motley Fool
- Hold Vodafone Group (VOD) by DZ Bank
- Buy Premier Foods (PFD) by Jefferies
- Buy Intermediate Capital Group (ICG) by Deutsche Bank
- Overweight WH Smith (SMWH) by JP Morgan
- Outperform TT Electronics (TTG) by RBC Capital
- Buy International Consolidated Airlines Group SA (CDI) (IAG) by Goldman Sachs
- Neutral Dr. Martens (DOCS) by Goldman Sachs
- Buy Intermediate Capital Group (ICG) by Goldman Sachs
- Neutral Vistry Group (VTY) by JP Morgan
- Buy Babcock International Group (BAB) by Jefferies
- Buy Convatec Group (CTEC) by Jefferies
- Buy Altona Rare Earths (REE) by Hot Stock Rockets in ShareProphets
- Avoid Marks Electrical Group (MRK) by Steve Moore in ShareProphets
- Buy Atalaya Mining (ATYM) by Canaccord Genuity
Hemogenyx Pharmaceuticals (HEMO) Share Price
Health Care Sector
NOTE: This is based on 3 open tips for Hemogenyx Pharmaceuticals (HEMO)
| Latest Bid : 1.00p | Latest Ask : 1.10p |
| High Today : 1.15p | Low Today : 1.00p |
| This Years High : 3.96p | This Years Low : 1.00p |
| Volume : 4,339,079 | MKT Cap : £14.75M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Hemogenyx Pharmaceuticals (HEMO) Overview
Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.Hemogenyx Pharmaceuticals (HEMO) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-11-11 12:10:00 11/11/2024 | 1.08% |
| Sell | Tom Winnifrith | Premium Only | 2024-10-02 12:20:00 02/10/2024 | 36.16% |
| Buy | Align Research Team | Premium Only | 2018-03-01 09:05:00 01/03/2018 | -39.31% |
Hemogenyx Pharmaceuticals (HEMO) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 1.00p | Latest Ask : 1.10p |
| High Today : 1.15p | Low Today : 1.00p |
| This Years High : 3.96p | This Years Low : 1.00p |
| Volume : 4,339,079 | MKT Cap : £14.75M |
Hemogenyx Pharmaceuticals Overview
Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Hemogenyx Pharmaceuticals Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-11-11 12:10:00 11/11/2024 | 1.08% |
| Sell | Tom Winnifrith | Premium Only | 2024-10-02 12:20:00 02/10/2024 | 36.16% |
| Buy | Align Research Team | Premium Only | 2018-03-01 09:05:00 01/03/2018 | -39.31% |